GSK May 2024 38.000 call
| Previous close | 3.3300 |
| Open | N/A |
| Bid | 5.9000 |
| Ask | 8.2000 |
| Strike | 38.00 |
| Expiry date | 2024-05-24 |
| Day's range | 3.3300 - 3.3300 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireBioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C financing round extended overall by CHF 12.3 million to CHF 44.9 million BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections
Investor's Business DailyGSK Stock Today: Buying An August Covered Call Boosts Your Return By This Much
A covered call strategy is one way to slightly reduce the risk on a long stock position while also generating some premium. Further upside in a covered call position in GSK stock is limited above the covered call strike. Let's look at how a covered call trade on GSK, formerly known as GlaxoSmithKline and based in the UK, might take shape.
Insider MonkeyGSK plc (NYSE:GSK) Q1 2024 Earnings Call Transcript
GSK plc (NYSE:GSK) Q1 2024 Earnings Call Transcript May 4, 2024 GSK plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Nick Stone: Hello everyone. Welcome to today’s call and webcast. The presentation was sent to our distribution list by email, and […]
